Urology Times staff

"In the moment, I think it's important to take a deep breath and try not to just be reactive," says Anne M. Suskind, MD, MS, FACS, FPMRS.

“The actions taken by those matched over 80% of the time. It seemed like what they saw, knowing the history, was a reasonable approximation of what an in-person urologist would do,” says Tracey L. Krupski, MD.

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD.

"We ultimately found that trans women from between the ages of 50 and 65 who were on hormone therapy had a 2.5-fold decreased risk of prostate cancer compared with cis men," says Matthew Loria.

“I think in actuality it's going to have to be one of our trained APPs going to these sites on a scheduled day, like the third Wednesday of every month,” says Tracey L. Krupski, MD.

"Like any test, it's really a very powerful tool. It's just how you deploy the tool," says Edward M. Schaeffer, MD, PhD.

“The hope is that we can collaborate with folks who might be interested in trying nadofaragene plus something else, something that compliments the mechanism of action, so that we can build upon what we have now,” says Vikram M. Narayan, MD.

"We hope that this paper encourages urologists to rethink non definitive treatment/active surveillance for prostate cancer and consider definitive treatment options earlier in the treatment pathway based on evidence that has accumulated," says Mital Patel, MD.

“I think 1 size doesn't fit all. We can't make a blanket statement that 1 of those types of therapy is better for all patients than another,” says Suzette E. Sutherland, MD, MS, FPMRS.

"We know that surgical intervention for ureteroscopy for both renal and ureteral stones does result in a relatively rapid and also quite substantial improvement in quality of life that does exceed preoperative baseline," says Justin B. Ziemba, MD, MSEd.

"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.

“I would just say that urologists should be focusing much more on the total amount of pattern 4, if they have that information available, than on the ratio of pattern 3 and 4, and therefore the grade group,” says Andrew J. Vickers, PhD.

"Because it takes advantage of a viral vector and is delivered as a gene therapy product, what it can do is it can have sustained release of IFNα2b in the bladder," says Vikram M. Narayan, MD.

"The point is healthy, adaptive changes that are sustainable, that you can keep off, because we don't want that rebound/regain," says Jill M. Hamilton-Reeves, PhD, RD, CSO.

"PSMA PET imaging is used in the initial diagnostic staging and then in subsequent cases where there can be a recurrence after primary treatment.," says Edward M. Schaeffer, MD, PhD.

“The 1 tweak that's different for our model is that the trained urologist is watching the cysto at the same time as the nurse practitioner is doing it,” says Tracey L. Krupski, MD.

"As most of us know, 1 in 8 couples undergo issues pertaining to fertility, and in about half of those cases, there is a male factor involved, resulting in infertility," says Akash Kapadia, MD.

"We must do more to help surgeons prepare for the impact of adverse events before they happen," says Kevin Turner MA DM FRCS(Urol).

"One notable finding was that veterans may not have access to the same quality of prostate cancer care as the US general population," says Olubiyi Aworunse, MD, MPH, PhD.

“I think the long and short of it is we know tibial nerve stimulation works, we're just trying to identify what's the best way by which we can deliver it conveniently and cost effectively to the patient,” says Suzette E. Sutherland, MD, MS, FPMRS.

"I continue to be regularly surprised at just how much surgeons are affected when things go wrong, and how little surgeons engage with existing support mechanisms," says Kevin Turner MA DM FRCS(Urol).

"What we did find was that a preoperative ureteral stent, and when we did semi rigid ureteroscopy initially, seemed to be protective against worse symptoms," says Justin B. Ziemba, MD, MSEd.

"Every time I leave the meeting, I just feel reinvigorated, refreshed, and excited about this field that we're a part of," says Raveen Syan, MD, FPMRS.

"The implications for urology, and every specialty, are immense. It does improve care, and it helps the patient. I think this is what it will be, it just may take some time," says Vipul Patel, MD.

In this video, Jaideep S. Sohi, MD, explains how the expanded information provided by PSMA-PET imaging allows physicians to more accurately tailor treatment plans for patients.

“We're always so focused on the prostate. That's the million-dollar question: are we getting to bladders too late?” says Kevin C. Zorn, MD, FRCSC, FACS.

In this video, Jaideep S. Sohi, MD, explains factors to consider regarding the timing of re-imaging with PSMA-PET in patients with prostate cancer.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

“What is becoming increasingly evident is that the traditional health care model is falling short for patients in rural regions,” says Ramy Abou Ghayda, MD, MPH, MBA candidate.

"PSMA-PET is a radio nucleotide-based imaging modality that really has changed the landscape of how we initially stage and subsequently follow individuals who have a diagnosis of prostate cancer," says Edward M. Schaeffer, MD, PhD.